Skip header and navigation

Refine By

57 records – page 1 of 6.

[A comparative analysis of the results of using different methods of helium-neon laser therapy in patients with stable stenocardia]

https://arctichealth.org/en/permalink/ahliterature11296
Source
Lik Sprava. 1996 Jan-Feb;(1-2):73-6
Publication Type
Article
Author
V M Iurlov
I H Kul'baba
Source
Lik Sprava. 1996 Jan-Feb;(1-2):73-6
Language
Ukrainian
Publication Type
Article
Keywords
Angina Pectoris - drug therapy - metabolism - radiotherapy
Antithrombin III - metabolism - radiation effects
Chronic Disease
Combined Modality Therapy
Comparative Study
English Abstract
Evaluation Studies
Humans
Lasers - therapeutic use
Liver - metabolism - radiation effects
Nitroglycerin - therapeutic use
Vasodilator Agents - therapeutic use
alpha 1-Antitrypsin - metabolism - radiation effects
alpha-Macroglobulins - metabolism - radiation effects
Abstract
Based on the findings from the examination of 133 patients with stable angina pectoris, it was shown that He-Ne laser therapy with the irradiation being applied to the liver projection area in combination with the prolonged-action nitrates is superior to similar application of irradiation to the precordial region and Head's zones or intravenous irradiation of blood. Revealed in the examination of the above patients was a reaction of antiproteolytic enzymes to He-Ne laser therapy, which appeared to be varying with methods of laser therapy. It is suggested that a reaction of the realization of the components of proteolysis might be involved in the realization of therapeutic effect of the He-Ne laser energy in patients with ischemic heart disease.
PubMed ID
9005112 View in PubMed
Less detail

Acute heart failure: lessons learned so far.

https://arctichealth.org/en/permalink/ahliterature134305
Source
Can J Cardiol. 2011 May-Jun;27(3):284-95
Publication Type
Article
Author
Jonathan G Howlett
Author Affiliation
Department of Cardiac Sciences, University of Calgary, and Libin Cardiovascular Institute, Calgary, Alberta, Canada. jonathan.howlett@cdha.nshealth.ca
Source
Can J Cardiol. 2011 May-Jun;27(3):284-95
Language
English
Publication Type
Article
Keywords
Acute Disease
Canada
Cardiotonic Agents - therapeutic use
Diuretics - therapeutic use
Drug Therapy, Combination
Early Diagnosis
Female
Heart Failure - diagnosis - drug therapy - mortality
Hospitalization - statistics & numerical data
Humans
Male
Prognosis
Randomized Controlled Trials as Topic
Risk assessment
Severity of Illness Index
Survival Analysis
Treatment Outcome
Vasodilator Agents - therapeutic use
Abstract
Acute heart failure (AHF) affects nearly every Canadian with heart failure (HF) at least once. Despite several attempts, no medical therapies have been shown to improve the natural history of AHF. In addition, the place of diagnosis of AHF is increasingly made in the outpatient setting. In this view, AHF is a moving target, and from recent registry data and from clinical trials, 5 critical lessons regarding the syndrome of AHF emerge: (1) The period of clinical instability preceding AHF may be much longer than previously thought. (2) Refinement of tools used to aid the early and accurate diagnosis of AHF will impact patient outcomes. (3) Standard supportive care of patients with AHF includes early use of diuretics with frequent reassessment in nearly all patients and supplemental vasodilators and oxygen therapy in selected cases. (4) Patients who survive presentation of AHF continue to suffer high rates of re-presentation, death, and rehospitalization following discharge from either hospital or emergency department. (5) Interventions shown to improve patient outcomes for AHF to date are related to process of care rather than new medications or devices. This report reviews the recent literature regarding the presentation, diagnosis, management, and prognosis of AHF. Areas of future research priority are indicated and guidelines for improving treatment are provided. AHF is an important clinical area that has not been as intensively studied as chronic HF; it presents both important needs and exciting opportunities for research and innovation.
PubMed ID
21601768 View in PubMed
Less detail

[Assessment of clinical course, prognosis and effectiveness of drug and nondrug treatment of patients with ischemic heart disease and occlusive coronary artery atherosclerosis (data of 5-year prospective follow-up)].

https://arctichealth.org/en/permalink/ahliterature168056
Source
Kardiologiia. 2006;46(6):4-9
Publication Type
Article
Date
2006
Author
S E Evstifeeva
V P Lupanov
A N Samko
V G Naumov
Source
Kardiologiia. 2006;46(6):4-9
Date
2006
Language
Russian
Publication Type
Article
Keywords
Adult
Aged
Angioplasty, Balloon, Coronary
Coronary Angiography
Coronary Artery Bypass
Coronary Artery Disease - mortality - radiography - therapy
Follow-Up Studies
Humans
Male
Middle Aged
Prospective Studies
Russia - epidemiology
Survival Rate
Treatment Outcome
Vasodilator Agents - therapeutic use
Abstract
Data of 5-year prospective follow-up were used for assessment of clinical course, prognosis and effectiveness of drug and nondrug treatment of 202 patients with ischemic heart disease, occlusive coronary artery atherosclerosis and preserved left ventricular function. It was found that 5-year cardiovascular mortality and rate of nonfatal myocardial infarction did not differ significantly between groups of patients subjected to drug treatment only, transluminal balloon angioplasty, and coronary artery bypass grafting.
PubMed ID
16883216 View in PubMed
Less detail

Association of air pollution and use of glyceryl trinitrate against angina pectoris: a population-based case-crossover study.

https://arctichealth.org/en/permalink/ahliterature114282
Source
Environ Health. 2013;12:38
Publication Type
Article
Date
2013
Author
Ragnhildur Gudrun Finnbjornsdottir
Helga Zoëga
Orn Olafsson
Throstur Thorsteinsson
Vilhjalmur Rafnsson
Author Affiliation
Center of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland.
Source
Environ Health. 2013;12:38
Date
2013
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Air Pollutants - analysis - toxicity
Angina Pectoris - chemically induced - drug therapy - epidemiology
Case-Control Studies
Cross-Over Studies
Environmental monitoring
Female
Humans
Hydrogen Sulfide - analysis - toxicity
Iceland - epidemiology
Inhalation Exposure
Logistic Models
Male
Middle Aged
Nitrogen Dioxide - analysis - toxicity
Nitroglycerin - therapeutic use
Ozone - analysis - toxicity
Particulate Matter - analysis - toxicity
Registries
Seasons
Urban Population
Vasodilator Agents - therapeutic use
Abstract
Ambient air pollution has been associated with increased cardiovascular morbidity and mortality. In Reykjavik, Iceland, air pollutant concentrations exceed official health limits several times every year. The aim was to study the association of concentrations of NO2, O3, PM10, and H2S in the Reykjavik capital area with the dispensing of anti-angina pectoris medication, glyceryl trinitrate to the inhabitants.
Data on daily dispensing of glyceryl trinitrate, were retrieved from the Icelandic Medicines Registry. Data on hourly concentrations of NO2, O3, PM10, and H2S were obtained from the Environment Agency of Iceland. A case-crossover design was used, based on the dispensing of glyceryl trinitrate to 5,246 individuals (=18 years) between 2005 and 2009.
For every 10 µg/m3 increase of NO2 and O3 3-day mean concentrations, the odds ratio (OR) for daily dispensing of glyceryl trinitrates was 1.136 (95% confidence intervals (CI) 1.069-1.207) and 1.094 (95% CI 1.029-1.163) at lag 0, and OR was 1.096 (95% CI 1.029-1.168) and 1.094 (95% CI 1.028-1.166) at lag 1, respectively.
These findings suggest that NO2 and O3 ambient air concentrations may adversely affect cardiovascular health, as measured by the dispensing of glyceryl trinitrates for angina pectoris. Further, the findings suggest that data on the dispensing of medication may be a valuable health indicator when studying the effect of air pollution on cardiovascular morbidity.
Notes
Cites: Epidemiology. 2004 Jan;15(1):46-5614712146
Cites: Environ Res. 2004 May;95(1):43-5215068929
Cites: Am J Epidemiol. 1991 Jan 15;133(2):144-531985444
Cites: Occup Environ Med. 1997 Aug;54(8):535-409326156
Cites: Environ Health Perspect. 1999 Jul;107(7):521-510378998
Cites: Proc R Soc Med. 1965 May;58:295-30014283879
Cites: Environ Health Perspect. 2005 Feb;113(2):201-615687058
Cites: Circulation. 2005 Feb 8;111(5):563-915699276
Cites: Eur J Epidemiol. 2005;20(4):351-815971508
Cites: Am Heart J. 1999 Nov;138(5 Pt 1):890-910539820
Cites: Environ Res. 1999 Oct;81(3):224-3010585018
Cites: Epidemiology. 2001 Mar;12(2):193-911246580
Cites: Epidemiology. 2001 May;12(3):355-711337606
Cites: Circulation. 2001 Jun 12;103(23):2810-511401937
Cites: Circulation. 2002 Apr 2;105(13):1534-611927516
Cites: Arch Environ Health. 2002 Sep-Oct;57(5):405-1112641180
Cites: Environ Health Perspect. 2005 Aug;113(8):978-8216079066
Cites: Epidemiology. 2005 Nov;16(6):717-2616222160
Cites: Circulation. 2005 Nov 15;112(20):3073-916286602
Cites: Environ Res. 2006 Jun;101(2):238-4516169550
Cites: Am J Epidemiol. 2006 Sep 1;164(5):421-3316793862
Cites: Hypertension. 2007 Nov;50(5):970-617875820
Cites: Environ Res. 2009 Jan;109(1):51-819027107
Cites: N Engl J Med. 2009 Jan 22;360(4):376-8619164188
Cites: Chest. 2009 Mar;135(3):717-2319017882
Cites: Sci Total Environ. 2009 Aug 15;407(17):4826-3019501385
Cites: Basic Clin Pharmacol Toxicol. 2010 Feb;106(2):86-9419961477
Cites: Circulation. 2010 Jun 1;121(21):2331-7820458016
Cites: Environ Health Perspect. 2011 Aug;119(8):1130-521454146
Cites: BMJ. 2011;343:d553121933824
Cites: Environ Res. 2012 Feb;113:33-922264878
PubMed ID
23631813 View in PubMed
Less detail

Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT).

https://arctichealth.org/en/permalink/ahliterature148799
Source
Hypertension. 2009 Nov;54(5):1009-13
Publication Type
Article
Date
Nov-2009
Author
Charlotte Manisty
Jamil Mayet
Robyn J Tapp
Peter S Sever
Neil Poulter
Simon A McG Thom
Alun D Hughes
Author Affiliation
International Centre for Circulatory Health, Imperial College London & Imperial College Healthcare NHS Trust, London W2 1LA, UK.
Source
Hypertension. 2009 Nov;54(5):1009-13
Date
Nov-2009
Language
English
Publication Type
Article
Keywords
Aged
Amlodipine - therapeutic use
Ankle Brachial Index
Anticholesteremic Agents - therapeutic use
Antihypertensive Agents - therapeutic use
Blood Pressure Determination
Carotid Arteries - drug effects - physiology
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Female
Great Britain
Heptanoic Acids - therapeutic use
Humans
Hypertension - diagnosis - drug therapy
Male
Middle Aged
Multivariate Analysis
Probability
Prospective Studies
Pulsatile Flow - drug effects
Pyrroles - therapeutic use
Reproducibility of Results
Scandinavia
Severity of Illness Index
Vasodilator Agents - therapeutic use
Abstract
Hydroxymethylglutaryl-CoA reductase inhibitors (statins) reduce cardiovascular events in hypertensive subjects, but their effect on carotid BP, pressure augmentation, and wave reflection is unknown. We compared the effect of atorvastatin with placebo in a substudy of the lipid-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA). Hypertensive patients (n=142; age=43 to 79 years; 127 male) with total cholesterol
Notes
Comment In: Hypertension. 2009 Nov;54(5):958-919720953
PubMed ID
19720956 View in PubMed
Less detail

[Barriers to prevention of cerebrovascular complications of hypertension].

https://arctichealth.org/en/permalink/ahliterature107587
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(7):16-20
Publication Type
Article
Date
2013
Author
A E Manoilov
K R Faizullin
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(7):16-20
Date
2013
Language
Russian
Publication Type
Article
Keywords
Antihypertensive Agents - therapeutic use
Cerebrovascular Disorders - epidemiology - etiology - prevention & control
Female
Humans
Hypertension - complications - drug therapy - physiopathology
Incidence
Male
Middle Aged
Questionnaires
Risk factors
Russia - epidemiology
Treatment Outcome
Vasodilator Agents - therapeutic use
Abstract
An analysis of well-established aspects of stroke prevention is presented. The authors present results of the questionnaire survey of 286 primary care physicians of six regions of Russia (Chelyabinsk, Kurgan, Orenburg, Saratov, Sverdlovsk Oblasts and the Republic of Bashkortostan). Most of respondents (71.68%, 95% CI: 66.08-76.83) have reported that ischemic stroke often develops due to vasospasm and / or reduction of the cerebral blood flow during systemic hypotension; 91.26% (95% CI: 87.37-94.26) of surveyed physicians use vasodilators and metabolic agents for prevention of stroke and 67.48% (95% CI: 61.72-72.88) administer treatment similar to that used after a transient ischemic attack. Approximately half of the physicians prefers maintaining the normal blood pressure in elderly as a preventive measure of the first and second stroke events.
PubMed ID
23994914 View in PubMed
Less detail

Can an educational program optimize PDE5i therapy? A study of Canadian primary care practices.

https://arctichealth.org/en/permalink/ahliterature162442
Source
J Sex Med. 2007 Sep;4(5):1404-13
Publication Type
Article
Date
Sep-2007
Author
Gerald Brock
Serge Carrier
Richard Casey
Jean-Eric Tarride
Stacey Elliott
Hélène Dugré
Catherine Rousseau
Pina D'Angelo
Isabelle Defoy
Author Affiliation
Department of Urology, St. Joseph's Healthcare, London, Ontario, Canada.
Source
J Sex Med. 2007 Sep;4(5):1404-13
Date
Sep-2007
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Canada - epidemiology
Combined Modality Therapy
Erectile Dysfunction - drug therapy - prevention & control
Humans
Male
Middle Aged
Patient Education as Topic - methods
Patient Satisfaction - statistics & numerical data
Phosphodiesterase Inhibitors - therapeutic use
Piperazines - therapeutic use
Primary Health Care - organization & administration
Professional-Patient Relations
Prospective Studies
Purines - therapeutic use
Sulfones - therapeutic use
Treatment Outcome
Vasodilator Agents - therapeutic use
Abstract
The importance of patient instructions, designed to optimize therapy with phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction (ED), has recently been demonstrated.
To evaluate the impact of an educational program for new sildenafil users against usual ED management in Canadian primary care practices.
This multicenter, 6-month cluster randomized prospective study was conducted across Canada in general practitioners' offices where sites were randomized to receive a treatment optimization program (TOP) tool at visit 1 (TOP sites) or not to receive the TOP tool (non-TOP sites) while continuing with usual practice. Study participants were men seeking medical attention for ED and who were sildenafil naïve. The TOP tool consisted of a tear-off sheet, a brochure, and a video. Study drug was not provided to the patients. Sildenafil samples and prescriptions were dispensed as per usual care practices.
The Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire was used to determine treatment satisfaction at visit 2 (month 3) and visit 3 (month 6). Patient and physician satisfaction with the TOP tool was assessed using self-reported questionnaires.
The intent-to-treat (ITT) population consisted of 2,573 patients from 231 primary care sites. At visits 2 and 3, treatment satisfaction with sildenafil was high with almost 9 patients out of 10 satisfied with treatment. No significant statistical differences were observed in the EDITS scores between the TOP and the non-TOP groups at visits 2 and 3. More than 80% of the participants were satisfied or very satisfied with the video and the brochure. More than 8 out of 10 participating physicians (84%) would use the TOP tool in their current practice if available.
TOP is a valuable and time-efficient ED management tool providing benefits to newly diagnosed ED patients and to their physicians.
PubMed ID
17634053 View in PubMed
Less detail

[Chronic heart failure--suggestion to a management program]

https://arctichealth.org/en/permalink/ahliterature54165
Source
Tidsskr Nor Laegeforen. 1999 Sep 30;119(23):3427-31
Publication Type
Article
Date
Sep-30-1999
Author
A. Westheim
K. Dickstein
T. Gundersen
T. Hole
J. Kjekshus
E S Myhre
P K Rønnevik
S. Samstad
P. Smith
Author Affiliation
Hjertemedisinsk avdeling, Ullevål sykehus, Oslo.
Source
Tidsskr Nor Laegeforen. 1999 Sep 30;119(23):3427-31
Date
Sep-30-1999
Language
Norwegian
Publication Type
Article
Keywords
Adrenergic beta-Antagonists - therapeutic use
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Anticholesteremic Agents - therapeutic use
Anticoagulants - therapeutic use
Digitalis Glycosides - therapeutic use
Diuretics - therapeutic use
English Abstract
Guidelines
Heart Failure, Congestive - diagnosis - drug therapy
Humans
Norway
Regional Medical Programs
Societies, Medical
Vasodilator Agents - therapeutic use
Abstract
In 1994, a Norwegian programme for diagnosis and treatment of chronic heart failure was published. Recently the American College of Cardiology, the American Heart Association and the Task Force on Heart Failure of the European Society of Cardiology have published similar guidelines. In this article, the Working Group on Heart Failure of the Norwegian Society of Cardiology presents an updated programme for evaluation and management of patients with chronic heart failure.
PubMed ID
10553340 View in PubMed
Less detail

57 records – page 1 of 6.